NeoTX Therapeutics Ltd.

2 clinical trials · Sponsor

Record	Firm	Date
NAP in Combination With Docetaxel Following Obinutuzumab Pretreatment in Subjects With Checkpoint Inhibitor Pretreated Advanced or Metastatic NSCLC (NCT04880863)	NeoTX Therapeutics Ltd.	2021-10-26
Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer. (NCT03983954)	NeoTX Therapeutics Ltd.	2019-10-10

Every clearance here is in the API, with alerts when new ones post.